Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4431-5. doi: 10.1016/j.bmcl.2003.09.026.

Authors

Feroze Ujjainwalla¹, Daniel Warner, Thomas F Walsh, Matthew J Wyvratt, Changyou Zhou, Lihu Yang, Rubana N Kalyani, Tanya MacNeil, Lex H T Van der Ploeg, Charles I Rosenblum, Rui Tang, Aurawan Vongs, David H Weinberg, Mark T Goulet

Affiliation

¹ Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. [email protected]

PMID: 14643340
DOI: 10.1016/j.bmcl.2003.09.026

Abstract

The discovery and optimization of a new class of non-peptidyl, pyridazinone derived melanocortin subtype-4 receptor agonists is disclosed.

MeSH terms

Animals
Binding Sites
Humans
Indicators and Reagents
Kinetics
Mice
Molecular Conformation
Pyridazines / chemical synthesis*
Pyridazines / chemistry
Pyridazines / pharmacology*
Receptor, Melanocortin, Type 4 / agonists*
Stereoisomerism
Structure-Activity Relationship

Substances

Indicators and Reagents
Pyridazines
Receptor, Melanocortin, Type 4